Recruiting
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants - IM027-1012
Actualizado: 7 marzo, 2025 | ClinicalTrials.gov
Fase
Sexo(s)
Intervalo de edad
Lugar(es)
Recruiting
Inclusion Criteria: - Female individuals not of childbearing potential (INOCBP) and males. - Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments. - Body mass index (BMI) 18.0 to 32.0 kg/m2 , inclusive, for Parts A and B. Exclusion Criteria: - Any significant acute or chronic medical illness as determined by the investigator. - History of clinically relevant cardiac disease as determined by the investigator, symptomatic or asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors for ventricular arrhythmias. - Any significant history of disease of the cardiovascular system that in the opinion of the Investigator makes the participant unsuitable for enrollment into the study. - Other protocol-defined inclusion/exclusion criteria apply.
Recomendamos encarecidamente que se comunique con BMS para informar de los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica
